Ipca Laboratories Limited (IPCALAB.NS) fair value

ACCE thesis

Ipca Laboratories makes branded generics and active pharmaceutical ingredients, with a large franchise in chronic therapies such as its cardiac and anti-diabetic lines in India, alongside a regulated-market export business for generic APIs and formulations. The structural case rests on its India branded formulations business, where a field-force model gives it share in prescriber-led categories that are hard for new entrants to displace. Revenue growth of 20.8% is well ahead of what most Indian pharma peers are posting, and a 67.7% gross margin is consistent with a specialty mix rather than commodity generics. The stock trades at 36.9x trailing earnings but 27.0x forward, which implies the market expects earnings to grow substantially faster than the top line over the next year. For a concentrated book, the question is whether that earnings step-up is visible in order flow and margin trajectory, and whether the 20.0% operating margin can hold as the export mix shifts.